Exactly and all these basher say the money is a problem. I see it all the time with these bio stocks. I just saw one today get a 90 million dollar licensing deal today with up front money. The company had one indication I believe. Imagine if we had several deals done at once ?

Now I don’t want to get my hopes up because I think we are still a few years off from double digits. Maybe…

However, I’ve seen stranger things. If we partner with a bunch of companies all bets are off as to where this thing can go and how long it will take.

People have to remember this is not a normal company. It’s a platform drug. Not just one with 2-3 indications. We are talking dozens of indications.

Jazz’s market cap isn’t even high. Cytodny could make GILDs market cap look like a joke and even J&Js if this matures the way it should. I just hope we don’t do some NASH partnership deal. 4 years fly by and we get some offer after the phase 3 results for 10 dollars. That seems to be the trends for these companies. The buyouts are low. IMMU had a decent buyout I had my eyes on it at 10 and then next thing I know it was at 80. Still I’d rather see this grow into a major company.

I’m all set with 5 dollars even though I’ll be well into six figures with this stock at that point.

I guess we will have to wait and see.